11 – 20 of 72
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden
(
- Contribution to journal › Article
-
Mark
Germline variants at SOHLH2 influence multiple myeloma risk
(
- Contribution to journal › Article
-
Mark
Bone Marrow Neutrophils of Multiple Myeloma Patients Exhibit Myeloid-Derived Suppressor Cell Activity
(
- Contribution to journal › Article
- 2020
-
Mark
Genetic predisposition for multiple myeloma
(
- Contribution to journal › Scientific review
-
Mark
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
(
- Contribution to journal › Article
-
Mark
Outcome and characteristics of non-measurable myeloma : A cohort study with population-based data from the Swedish Myeloma Registry
(
- Contribution to journal › Article
-
Mark
Search for multiple myeloma risk factors using Mendelian randomization
(
- Contribution to journal › Article
-
Mark
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression : A prospective, open-label, multicenter, randomized, phase 3 study
(
- Contribution to journal › Article
-
Mark
Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma : The HOVON-87/NMSG-18 trial
(
- Contribution to journal › Article
-
Mark
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
(
- Contribution to journal › Article